ANTHONY B. HODSMAN, M.B.; DONALD J. SHERRARD, M.D.; EUGENE G. C. WONG, M.D.; ARNOLD S. BRICKMAN, M.D.; DAVID B. N. LEE, M.D.; ALLAN C. ALFREY, M.D.; FREDERICK R. SINGER, M.D.; ANTHONY W. NORMAN, Ph.D.; JACK W. COBURN, M.D.
We describe a sporadic, vitamin-D-resistant osteomalacic syndrome in 19 patients undergoing hemodialysis. The syndrome was found in less than 1.5% of patients from referring dialysis centers. All 19 patients had multiple fractures, severe myopathy, and many developed spontaneous hypercalcemia. Severe osteomalacia without evidence of secondary hyperparathyroidism distinguished this syndrome from other forms of renal osteodystrophy. Bone aluminum, measured in six patients, was greatly elevated. Therapy with calcitriol (1α, 25-dihydroxycholecalciferol) led to clinical improvement in seven patients with reduced pain and myopathy, decreased serum alkaline phosphatase, or both, but no improvement in bone histology. Patients who did not respond clinically to calcitriol developed marked hypercalcemia. The cause of this severe osteomalacia, which occurs despite normal or slightly elevated levels of serum calcium and phosphorus and fails to mineralize with calcitriol, is unclear.
HODSMAN AB, SHERRARD DJ, WONG EGC, et al. Vitamin-D-Resistant Osteomalacia in Hemodialysis Patients Lacking Secondary Hyperparathyroidism. Ann Intern Med. 1981;94:629–637. doi: 10.7326/0003-4819-94-5-629
Download citation file:
Published: Ann Intern Med. 1981;94(5):629-637.
Endocrine and Metabolism, Metabolic Bone Disorders, Nephrology, Parathyroid Disorders, Renal Replacement Therapy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use